ePrints

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

Lookup NU author(s): Dr David Jamieson, Melanie Griffin, Julieann Sludden, Dr Yvette DrewORCiD, Dr Nicola Cresti, Professor Alastair GreystokeORCiD

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Publication metadata

Author(s): Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R

Publication type: Article

Publication status: Published

Journal: European Journal of Cancer

Year: 2016

Volume: 68

Pages: 1-10

Print publication date: 01/11/2016

Online publication date: 28/09/2016

Acceptance date: 27/08/2016

Date deposited: 30/11/2016

ISSN (print): 0959-8049

ISSN (electronic): 1879-0852

Publisher: Pergamon Press

URL: http://dx.doi.org/10.1016/j.ejca.2016.08.026

DOI: 10.1016/j.ejca.2016.08.026

Altmetrics

Share